Emergent BioSolutions (EBS) EBIT (2011 - 2026)

Emergent BioSolutions' EBIT history runs 16 years deep, the most recent figure standing at $10.5 million for Q1 2026.

• On a quarterly basis, EBIT fell 78.96% year-over-year to $10.5 million in Q1 2026; TTM through Mar 2026 was $60.7 million, a 161.56% increase from a year earlier, with the FY2025 full-year figure at $100.1 million, up 192.09% from the prior year.
• EBIT rose to $10.5 million in Q1 2026 per EBS's latest filing, from -$27.9 million in the prior quarter.
• Across five years, EBIT topped out at $76.5 million in Q3 2025 and bottomed at -$292.9 million in Q2 2023.
• The 5-year median for EBIT is -$27.9 million (2025), against an average of -$52.6 million.
• Across the five-year window, EBIT slumped 2239.13% in 2023 and soared 126.96% in 2024, its largest moves.
• Year by year, EBIT stood at -$55.3 million in 2022, then advanced by 20.8% to -$43.8 million in 2023, then soared by 78.31% to -$9.5 million in 2024, then slumped by 193.68% to -$27.9 million in 2025, then surged by 137.63% to $10.5 million in 2026.
• Per Business Quant, the three latest EBS EBIT figures stand at $10.5 million (Q1 2026), -$27.9 million (Q4 2025), and $76.5 million (Q3 2025).